Literature DB >> 23531502

Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis.

Roshni C George1, John Lew, Donald J Graves.   

Abstract

Abnormal modifications in tau such as hyperphosphorylation, oxidation, and glycation interfere with its interaction with microtubules leading to its dissociation and self-aggregation into neurofibrillary tangles, a hallmark of Alzheimer's disease (AD). Previously we reported that an aqueous extract of cinnamon has the ability to inhibit tau aggregation in vitro and can even induce dissociation of tangles isolated from AD brain. In the present study, we carried out investigations with cinnamaldehyde (CA) and epicatechin (EC), two components of active cinnamon extract. We found that CA and the oxidized form of EC (ECox) inhibited tau aggregation in vitro and the activity was due to their interaction with the two cysteine residues in tau. Mass spectrometry of a synthetic peptide, SKCGS, representing the actual tau sequence, identified the thiol as reacting with CA and ECox. Use of a cysteine double mutant of tau showed the necessity of cysteine for aggregation inhibition by CA. The interaction of CA with tau cysteines was reversible and the presence of CA did not impair the biological function of tau in tubulin assembly in vitro. Further, these compounds protected tau from oxidation caused by the reactive oxygen species, H2O2, and prevented subsequent formation of high molecular weight species that are considered to stimulate tangle formation. Finally, we observed that EC can sequester highly reactive and toxic byproducts of oxidation such as acrolein. Our results suggest that small molecules that form a reversible interaction with cysteines have the potential to protect tau from abnormal modifications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23531502     DOI: 10.3233/JAD-122113

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  25 in total

1.  The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice.

Authors:  Angélica Maria Sabogal-Guáqueta; Juan Ignacio Muñoz-Manco; Jose R Ramírez-Pineda; Marisol Lamprea-Rodriguez; Edison Osorio; Gloria Patricia Cardona-Gómez
Journal:  Neuropharmacology       Date:  2015-02-07       Impact factor: 5.250

2.  The effects of Cinnamaldehyde on early brain injury and cerebral vasospasm following experimental subarachnoid hemorrhage in rabbits.

Authors:  Bora Gürer; Hayri Kertmen; Pınar Kuru Bektaşoğlu; Özden Çağlar Öztürk; Hüseyin Bozkurt; Abdullah Karakoç; Ata Türker Arıkök; Erhan Çelikoğlu
Journal:  Metab Brain Dis       Date:  2019-08-23       Impact factor: 3.584

Review 3.  Advances in protein misfolding, amyloidosis and its correlation with human diseases.

Authors:  Debanjan Kundu; Kumari Prerna; Rahul Chaurasia; Manoj Kumar Bharty; Vikash Kumar Dubey
Journal:  3 Biotech       Date:  2020-04-04       Impact factor: 2.406

Review 4.  Structure and mechanism of action of tau aggregation inhibitors.

Authors:  Katryna Cisek; Grace L Cooper; Carol J Huseby; Jeff Kuret
Journal:  Curr Alzheimer Res       Date:  2014       Impact factor: 3.498

5.  Inactivation of CYP2A6 by the Dietary Phenylpropanoid trans-Cinnamic Aldehyde (Cinnamaldehyde) and Estimation of Interactions with Nicotine and Letrozole.

Authors:  Jeannine Chan; Tyler Oshiro; Sarah Thomas; Allyson Higa; Stephen Black; Aleksandar Todorovic; Fawzy Elbarbry; John P Harrelson
Journal:  Drug Metab Dispos       Date:  2016-02-05       Impact factor: 3.922

Review 6.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 7.  Natural product-based amyloid inhibitors.

Authors:  Paul Velander; Ling Wu; Frances Henderson; Shijun Zhang; David R Bevan; Bin Xu
Journal:  Biochem Pharmacol       Date:  2017-04-06       Impact factor: 5.858

Review 8.  Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease.

Authors:  Pritam Thapa; Sunil P Upadhyay; William Z Suo; Vikas Singh; Prajwal Gurung; Eung Seok Lee; Ram Sharma; Mukut Sharma
Journal:  Bioorg Chem       Date:  2021-01-29       Impact factor: 5.307

9.  Oral (-)-Epicatechin Inhibits Progressive Tau Pathology in rTg4510 Mice Independent of Direct Actions at GSK3β.

Authors:  Katriona L Hole; Lydia E Staniaszek; Gayathri Menon Balan; Jody M Mason; Jon T Brown; Robert J Williams
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

10.  (-)-Epicatechin protects hemorrhagic brain via synergistic Nrf2 pathways.

Authors:  Che-Feng Chang; Suzy Cho; Jian Wang
Journal:  Ann Clin Transl Neurol       Date:  2014-04-01       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.